Global In Vitro Diagnostics (IVD) Market: Drivers, Opportunities, Trends and Forecasts: 2014 - 2020
Global In-Vitro Diagnostics Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023
Overview:
In-vitro diagnostics is a process of diagnosing various medical conditions using assay kits and analyzers. The in-vitro diagnostics (IVD) market is growing at a steady rate as there is an increase in the awareness of various diseases and various plans are initiated by the government to reduce the diseases. Most of the IVD tests are performed in medical and clinical laboratories but the advent of point-of-care (POC) technology has enabled testing to be performed in the presence of the patient and even at their home. This technology advancement is driving market growth during the forecast period.
Factors, such as increasing lifestyle diseases, growing adoption of POC testing, increasing demand for biomarker-based testing and demand from the emerging countries are expected to drive the market growth during the forecast period. The increased sales of counterfeit glucose monitoring strips and stringent regulatory approval processes are factors hampering the market growth.
The regulatory scenario is of concern as there has been a wide range of instruments and assays, which range from Class I to Class III devices. Recently there has been a change in regulations in the European region, which has been a major issue for the market players.
The market is witnessing an emerging trend for noninvasive prenatal testing, next-generation sequencing (NGS), liquid biopsy, and circulating tumor cells test. The markets in India, Brazil, and China are expected to grow at a rapid pace during the forecast period due to the high prevalence of infectious diseases in these countries.
Market Analysis:
The global in-vitro diagnostics market is estimated to witness a CAGR of 5.31% during the forecast period 2017–2023. The market is analyzed based on five segments – technology, application, test types, end-users, and regions.
Factors, such as increased sales of POC cardiac markers and increased adoption of DNA probe-based diagnostics are growth opportunities for the market players. The market is witnessing an emerging trend of companion diagnostics, cardiac biomarkers, POC markers, and other novel technologies that are helping in diagnosing the diseases at an early stage with precision. There has been a transition from diagnosis in core laboratories to diagnosis in front of the patient.
Regional Analysis:
The regions covered in the in-vitro diagnostics market report are the Americas, EMEA, APAC, and Rest of the World (ROW). The Americas is set to be the leading region for the IVD market growth followed by Europe. Asia Pacific and ROW are set to be the emerging regions. The markets in India, Brazil, and China are expected to grow at a rapid pace during the forecast period as the prevalence of infectious diseases and lifestyle diseases in these countries is high. These countries are set to be the target regions for the market players due to the large untapped potential.
Technology Analysis:
The global IVD market is segmented by the following technologies- immunoassay, clinical chemistry, clinical microbiology, molecular diagnostics, hematology, and coagulation. The clinical chemistry market is currently leading the market with a share of 32.2% due to the high prevalence of diabetes. India has the highest rate of diabetes, making Asia Pacific the region for future investments. The molecular diagnostics segment is expected to have the fastest growth rate during the forecast period. Technological advancements in various molecular diagnostics technology, such as PCR and NGS, are driving the market. The market is also witnessing various M&A and collaborations among the top players, which are defining the future of the global IVD market.
Test Types Analysis:
Core laboratory holds the major share of the market but the advantages of POC technology are expected to make it the fastest growing test type.
Application Analysis:
Among the various diagnostic areas, infectious diseases hold the major share of the market followed by diabetes. But the increasing prevalence of cancer is expected to make it the fastest growing segment.
Key Players:
The leader in IVD market is F. Hoffmann-La Roche, who is currently occupying 20% of the IVD market. Abbott, Siemens, Danaher, and ThermoFisher are the other major players in the market. These top players occupy around 56% of the market. The report covers the following players:
The clinical chemistry segment is dominating the global IVD market, and a lot of new players are focusing on developing technologically advanced reagents and analyzers to gain market share. Novel technologies, such as prenatal testing, liquid biopsy, and cardiac biomarkers, are expected to drive the market growth in the future.
Large players, such as F. Hoffmann-La Roche, Danaher, and Abbott, are acquiring companies with products that would complement their existing portfolio. For instance, in November 2016, Danaher acquired Cepheid and in February 2016, Abbott signed an agreement to acquire Alere, a leader in POC technology. Furthermore, most of the companies are aiming to obtain a waiver of the Clinical Laboratory Improvement Amendments of 1988 for their products to increase their sales. Significant investments in R&D in this market is expected to increase, and collaborations and M&A are expected to continue.
Benefits:
The report provides complete details about the usage and the adoption rate of IVD by various end-users and regions. The key stakeholders use this information to know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards increasing disease awareness, along with the details of commercial devices available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about business opportunities to key stakeholders to expand their business and increase revenue in the specific vertical and to analyze before investing or expanding business in this market.
Key Stakeholders
Overview:
In-vitro diagnostics is a process of diagnosing various medical conditions using assay kits and analyzers. The in-vitro diagnostics (IVD) market is growing at a steady rate as there is an increase in the awareness of various diseases and various plans are initiated by the government to reduce the diseases. Most of the IVD tests are performed in medical and clinical laboratories but the advent of point-of-care (POC) technology has enabled testing to be performed in the presence of the patient and even at their home. This technology advancement is driving market growth during the forecast period.
Factors, such as increasing lifestyle diseases, growing adoption of POC testing, increasing demand for biomarker-based testing and demand from the emerging countries are expected to drive the market growth during the forecast period. The increased sales of counterfeit glucose monitoring strips and stringent regulatory approval processes are factors hampering the market growth.
The regulatory scenario is of concern as there has been a wide range of instruments and assays, which range from Class I to Class III devices. Recently there has been a change in regulations in the European region, which has been a major issue for the market players.
The market is witnessing an emerging trend for noninvasive prenatal testing, next-generation sequencing (NGS), liquid biopsy, and circulating tumor cells test. The markets in India, Brazil, and China are expected to grow at a rapid pace during the forecast period due to the high prevalence of infectious diseases in these countries.
Market Analysis:
The global in-vitro diagnostics market is estimated to witness a CAGR of 5.31% during the forecast period 2017–2023. The market is analyzed based on five segments – technology, application, test types, end-users, and regions.
Factors, such as increased sales of POC cardiac markers and increased adoption of DNA probe-based diagnostics are growth opportunities for the market players. The market is witnessing an emerging trend of companion diagnostics, cardiac biomarkers, POC markers, and other novel technologies that are helping in diagnosing the diseases at an early stage with precision. There has been a transition from diagnosis in core laboratories to diagnosis in front of the patient.
Regional Analysis:
The regions covered in the in-vitro diagnostics market report are the Americas, EMEA, APAC, and Rest of the World (ROW). The Americas is set to be the leading region for the IVD market growth followed by Europe. Asia Pacific and ROW are set to be the emerging regions. The markets in India, Brazil, and China are expected to grow at a rapid pace during the forecast period as the prevalence of infectious diseases and lifestyle diseases in these countries is high. These countries are set to be the target regions for the market players due to the large untapped potential.
Technology Analysis:
The global IVD market is segmented by the following technologies- immunoassay, clinical chemistry, clinical microbiology, molecular diagnostics, hematology, and coagulation. The clinical chemistry market is currently leading the market with a share of 32.2% due to the high prevalence of diabetes. India has the highest rate of diabetes, making Asia Pacific the region for future investments. The molecular diagnostics segment is expected to have the fastest growth rate during the forecast period. Technological advancements in various molecular diagnostics technology, such as PCR and NGS, are driving the market. The market is also witnessing various M&A and collaborations among the top players, which are defining the future of the global IVD market.
Test Types Analysis:
Core laboratory holds the major share of the market but the advantages of POC technology are expected to make it the fastest growing test type.
Application Analysis:
Among the various diagnostic areas, infectious diseases hold the major share of the market followed by diabetes. But the increasing prevalence of cancer is expected to make it the fastest growing segment.
Key Players:
The leader in IVD market is F. Hoffmann-La Roche, who is currently occupying 20% of the IVD market. Abbott, Siemens, Danaher, and ThermoFisher are the other major players in the market. These top players occupy around 56% of the market. The report covers the following players:
- F. Hoffmann-La Roche
- ThermoFisher Scientific
- Danaher
- Siemens Healthineers
- Abbott
- Sysmex Corporation
- Ortho Clinical Diagnostics
- Bio-Rad Laboratories
- BioMeriux
- Becton Dickenson & Company
The clinical chemistry segment is dominating the global IVD market, and a lot of new players are focusing on developing technologically advanced reagents and analyzers to gain market share. Novel technologies, such as prenatal testing, liquid biopsy, and cardiac biomarkers, are expected to drive the market growth in the future.
Large players, such as F. Hoffmann-La Roche, Danaher, and Abbott, are acquiring companies with products that would complement their existing portfolio. For instance, in November 2016, Danaher acquired Cepheid and in February 2016, Abbott signed an agreement to acquire Alere, a leader in POC technology. Furthermore, most of the companies are aiming to obtain a waiver of the Clinical Laboratory Improvement Amendments of 1988 for their products to increase their sales. Significant investments in R&D in this market is expected to increase, and collaborations and M&A are expected to continue.
Benefits:
The report provides complete details about the usage and the adoption rate of IVD by various end-users and regions. The key stakeholders use this information to know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards increasing disease awareness, along with the details of commercial devices available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about business opportunities to key stakeholders to expand their business and increase revenue in the specific vertical and to analyze before investing or expanding business in this market.
Key Stakeholders
1 INDUSTRY OUTLOOK
1.1 Industry Overview
1.2 Industry Trends
1.3 Pest Analysis
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Total Addressable Market (TAM)
3.2 Segmented Addressable Market (SAM)
3.3 Related Markets
3.3.1 Medical Imaging
4 MARKET OUTLOOK
4.1 Market Definition – Infoholic Research
4.2 Importance of In-Vitro Diagnostics
4.3 Market Segmentation
4.4 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 Evolution
5.2 In-Vitro Diagnostics Advantages
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Increasing Lifestyle Diseases
5.3.1.2 Growing adoption of Point-of-Care testing
5.3.1.3 Increasing Demand for Biomarker Based Tests
5.3.1.4 High Growth of Market in Emerging Countries
5.3.2 Opportunities
5.3.2.1 Growing Significance of Companion Diagnostics
5.3.2.2 Increased Number of Mergers and Acquisitions
5.3.2.3 Increased Sales of POC Cardiac Markers
5.3.2.4 Increased Adoption of DNA Probe-based Diagnostics
5.3.3 Restraints
5.3.3.1 Stringent regulatory approvals
5.3.3.2 Increased sales of counterfeit glucose monitoring strips
5.3.4 DRO – Impact Analysis
5.3.5 Key Stakeholders
6 BY TECHNOLOGY: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Immunoassay
6.2.1 Enzyme-Linked Immunosorbent Assay (ELISA)
6.2.2 Radioimmunoassay (RIA)
6.2.3 Western Blot
6.3 Clinical Chemistry
6.3.1 Metabolic Panel
6.3.2 Electrolyte Panel
6.3.3 Liver Profile
6.3.4 Renal Panel
6.3.5 Lipid Profile
6.3.6 Thyroid Function Panel
6.3.7 Specialty Chemistry Tests
6.4 Molecular Diagnostics
6.4.1 Polymerase Chain Reaction (PCR)
6.4.2 Isothermal Nucleic Acid Amplification Technology (INAAT)
6.4.3 Microarray
6.4.4 Hybridization
6.4.5 DNA Sequencing
6.4.6 Other MDX technology
6.5 Clinical Microbiology
6.6 Hematology
6.7 Coagulation
6.8 Other IVD Technology
7 BY APPLICATION: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Oncology
7.3 Diabetes
7.4 Infectious Diseases
7.5 Cardiology
7.6 Autoimmune Disease
7.7 Drug Testing
7.8 Nephrology
7.9 Others
8 TEST TYPES: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 Core Laboratories Diagnostics
8.3 Point-of-Care Diagnostic
9 END USER: MARKET SIZE AND ANALYSIS
9.1 Overview
9.2 Hospitals
9.3 Laboratories
9.4 Home Care
9.5 Academics
9.6 Others
10 REGIONS: MARKET SIZE AND ANALYSIS
10.1 Overview
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.3.1 UK
10.3.2 Germany
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Turkey
10.4 APAC
10.4.1 India
10.4.2 China
10.4.3 Japan
10.5 Rest of the World
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Africa
11 COMPETITIVE LANDSCAPE
11.1 Overview
12 VENDOR PROFILES
12.1 F.Hoffmann-La Roche Ltd
12.1.1 Overview
12.1.2 Business Unit
12.1.3 Geographic Presence
12.1.4 Business Focus
12.1.5 SWOT Analysis
12.1.6 Business Strategy
12.2 Abbott Laboratories
12.2.1 Overview
12.2.2 Business Unit
12.2.3 Geographic Presence
12.2.4 Business Focus
12.2.5 SWOT Analysis
12.2.6 Business Strategy
12.3 Siemens Healthineers Inc.
12.3.1 Overview
12.3.2 Geographic Presence
12.3.3 Business Focus
12.3.4 SWOT Analysis
12.3.5 Business Strategy
12.4 Danaher Corporation.
12.4.1 Overview
12.4.2 Business Unit
12.4.3 Geographic Presence
12.4.4 Business Focus
12.4.5 SWOT Analysis
12.4.6 Business Strategy
12.5 Thermo Fisher Scientific Inc.
12.5.1 Overview
12.5.2 Geographic Presence
12.5.3 Business Focus
12.5.4 SWOT Analysis
12.5.5 Business Strategy
12.6 Sysmex Corp.
12.6.1 Overview
12.6.2 Business Unit
12.6.3 Geographic Presence
12.6.4 Business Focus
12.6.5 SWOT Analysis
12.6.6 Business Strategy
13 COMPANIES TO WATCH FOR
13.1 Becton Dickinson and Company
13.1.1 Overview
13.2 Ortho Clinical Diagnostics (Carlyle Group)
13.2.1 Overview
13.3 Bio-Rad Laboratories, Inc.
13.3.1 Overview
13.4 Qiagen NV
13.4.1 Overview
13.5 BioMerieux S.A.
13.5.1 Overview
Annexure
13.6 Abbreviations
Tables
Table 1 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TYPES, 2016–2023 ($BILLION)
Table 2 GLOBALIN-VITRO DIAGNOSTICS MARKET BY APPLICATION, 2016–2023 ($BILLION)
Table 3 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TEST TYPES SEGMENTATION, 2016–2023 ($BILLION)
Table 4 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USER SEGMENTATION, 2016–2023 ($BILLION)
Table 5 GLOBAL IN-VITRO DIAGNOSTICS MARKET REVENUE BY REGIONS, 2016–2023 ($BILLION)
Table 6 IN-VITRO DIAGNOSTICS MARKET BY VENDOR RANKING, 2016
Table 7 OTHER PROMINENT VENDORS IN THE MARKET
Table 8 F. HOFFMANN-LA ROCHE: OFFERINGS
Table 9 F. HOFFMANN-LA ROCHE.: RECENT DEVELOPMENTS
Table 10 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
Table 11 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
Table 12 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
Table 13 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
Table 14 DANAHER CORPORATION: OFFERINGS
Table 15 DANAHER CORPORATION: RECENT DEVELOPMENTS
Table 16 THERMOFISHER SCIENTIFIC: OFFERINGS
Table 17 THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS
Table 18 SYAMEX CORP: OFFERINGS
Table 19 SYSMEX CORP: RECENT DEVELOPMENTS
Table 20 BECTON DICKENSON AND COMPANY: RECENT DEVELOPMENTS
Table 21 ORTHO CLINICAL DIAGNOSTICS: RECENT DEVELOPMENTS
Table 22 BIO-RAD LABORATORIES: RECENT DEVELOPMENTS
Table 23 ORTHO CLINICAL DIAGNOSTICS: RECENT DEVELOPMENTS
Table 24 BIOMERIEUS: RECENT DEVELOPMENTS
1.1 Industry Overview
1.2 Industry Trends
1.3 Pest Analysis
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Total Addressable Market (TAM)
3.2 Segmented Addressable Market (SAM)
3.3 Related Markets
3.3.1 Medical Imaging
4 MARKET OUTLOOK
4.1 Market Definition – Infoholic Research
4.2 Importance of In-Vitro Diagnostics
4.3 Market Segmentation
4.4 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 Evolution
5.2 In-Vitro Diagnostics Advantages
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Increasing Lifestyle Diseases
5.3.1.2 Growing adoption of Point-of-Care testing
5.3.1.3 Increasing Demand for Biomarker Based Tests
5.3.1.4 High Growth of Market in Emerging Countries
5.3.2 Opportunities
5.3.2.1 Growing Significance of Companion Diagnostics
5.3.2.2 Increased Number of Mergers and Acquisitions
5.3.2.3 Increased Sales of POC Cardiac Markers
5.3.2.4 Increased Adoption of DNA Probe-based Diagnostics
5.3.3 Restraints
5.3.3.1 Stringent regulatory approvals
5.3.3.2 Increased sales of counterfeit glucose monitoring strips
5.3.4 DRO – Impact Analysis
5.3.5 Key Stakeholders
6 BY TECHNOLOGY: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Immunoassay
6.2.1 Enzyme-Linked Immunosorbent Assay (ELISA)
6.2.2 Radioimmunoassay (RIA)
6.2.3 Western Blot
6.3 Clinical Chemistry
6.3.1 Metabolic Panel
6.3.2 Electrolyte Panel
6.3.3 Liver Profile
6.3.4 Renal Panel
6.3.5 Lipid Profile
6.3.6 Thyroid Function Panel
6.3.7 Specialty Chemistry Tests
6.4 Molecular Diagnostics
6.4.1 Polymerase Chain Reaction (PCR)
6.4.2 Isothermal Nucleic Acid Amplification Technology (INAAT)
6.4.3 Microarray
6.4.4 Hybridization
6.4.5 DNA Sequencing
6.4.6 Other MDX technology
6.5 Clinical Microbiology
6.6 Hematology
6.7 Coagulation
6.8 Other IVD Technology
7 BY APPLICATION: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Oncology
7.3 Diabetes
7.4 Infectious Diseases
7.5 Cardiology
7.6 Autoimmune Disease
7.7 Drug Testing
7.8 Nephrology
7.9 Others
8 TEST TYPES: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 Core Laboratories Diagnostics
8.3 Point-of-Care Diagnostic
9 END USER: MARKET SIZE AND ANALYSIS
9.1 Overview
9.2 Hospitals
9.3 Laboratories
9.4 Home Care
9.5 Academics
9.6 Others
10 REGIONS: MARKET SIZE AND ANALYSIS
10.1 Overview
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.3.1 UK
10.3.2 Germany
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Turkey
10.4 APAC
10.4.1 India
10.4.2 China
10.4.3 Japan
10.5 Rest of the World
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Africa
11 COMPETITIVE LANDSCAPE
11.1 Overview
12 VENDOR PROFILES
12.1 F.Hoffmann-La Roche Ltd
12.1.1 Overview
12.1.2 Business Unit
12.1.3 Geographic Presence
12.1.4 Business Focus
12.1.5 SWOT Analysis
12.1.6 Business Strategy
12.2 Abbott Laboratories
12.2.1 Overview
12.2.2 Business Unit
12.2.3 Geographic Presence
12.2.4 Business Focus
12.2.5 SWOT Analysis
12.2.6 Business Strategy
12.3 Siemens Healthineers Inc.
12.3.1 Overview
12.3.2 Geographic Presence
12.3.3 Business Focus
12.3.4 SWOT Analysis
12.3.5 Business Strategy
12.4 Danaher Corporation.
12.4.1 Overview
12.4.2 Business Unit
12.4.3 Geographic Presence
12.4.4 Business Focus
12.4.5 SWOT Analysis
12.4.6 Business Strategy
12.5 Thermo Fisher Scientific Inc.
12.5.1 Overview
12.5.2 Geographic Presence
12.5.3 Business Focus
12.5.4 SWOT Analysis
12.5.5 Business Strategy
12.6 Sysmex Corp.
12.6.1 Overview
12.6.2 Business Unit
12.6.3 Geographic Presence
12.6.4 Business Focus
12.6.5 SWOT Analysis
12.6.6 Business Strategy
13 COMPANIES TO WATCH FOR
13.1 Becton Dickinson and Company
13.1.1 Overview
13.2 Ortho Clinical Diagnostics (Carlyle Group)
13.2.1 Overview
13.3 Bio-Rad Laboratories, Inc.
13.3.1 Overview
13.4 Qiagen NV
13.4.1 Overview
13.5 BioMerieux S.A.
13.5.1 Overview
Annexure
13.6 Abbreviations
Tables
Table 1 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TYPES, 2016–2023 ($BILLION)
Table 2 GLOBALIN-VITRO DIAGNOSTICS MARKET BY APPLICATION, 2016–2023 ($BILLION)
Table 3 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TEST TYPES SEGMENTATION, 2016–2023 ($BILLION)
Table 4 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USER SEGMENTATION, 2016–2023 ($BILLION)
Table 5 GLOBAL IN-VITRO DIAGNOSTICS MARKET REVENUE BY REGIONS, 2016–2023 ($BILLION)
Table 6 IN-VITRO DIAGNOSTICS MARKET BY VENDOR RANKING, 2016
Table 7 OTHER PROMINENT VENDORS IN THE MARKET
Table 8 F. HOFFMANN-LA ROCHE: OFFERINGS
Table 9 F. HOFFMANN-LA ROCHE.: RECENT DEVELOPMENTS
Table 10 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
Table 11 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
Table 12 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
Table 13 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
Table 14 DANAHER CORPORATION: OFFERINGS
Table 15 DANAHER CORPORATION: RECENT DEVELOPMENTS
Table 16 THERMOFISHER SCIENTIFIC: OFFERINGS
Table 17 THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS
Table 18 SYAMEX CORP: OFFERINGS
Table 19 SYSMEX CORP: RECENT DEVELOPMENTS
Table 20 BECTON DICKENSON AND COMPANY: RECENT DEVELOPMENTS
Table 21 ORTHO CLINICAL DIAGNOSTICS: RECENT DEVELOPMENTS
Table 22 BIO-RAD LABORATORIES: RECENT DEVELOPMENTS
Table 23 ORTHO CLINICAL DIAGNOSTICS: RECENT DEVELOPMENTS
Table 24 BIOMERIEUS: RECENT DEVELOPMENTS
LIST OF CHARTS
Chart 1 PEST ANALYSIS OF GLOBAL IN-VITRO DIAGNOSTICS MARKET
Chart 2 RESEARCH METHODOLOGY OF GLOBALIN-VITRO DIAGNOSTICS MARKET
Chart 3 GLOBAL IN-VITRO DIAGNOSTICS MARKET REVENUE FORECAST, 2016–2023 ($BILLION)
Chart 4 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY SEGMENTATION
Chart 5 PORTER 5 FORCES ON GLOBAL IN-VITRO DIAGNOSTISC MARKET
Chart 6 MARKET DYNAMICS – DRO ANALYSIS
Chart 7 DRO – IMPACT ANALYSIS OF GLOBAL IN-VITRO DIAGNOSTICS MARKET
Chart 8 KEY STAKEHOLDERS
Chart 9 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TYPE SEGMENTATION, 2016 (%)
Chart 10 GLOBAL IMMUNOASSAY MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 11 GLOBAL CLINICAL CHEMISTRY MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 12 GLOBAL OTHER MOLECULAR DIAGNOSTICS MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 13 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION, 2016 (%)
Chart 14 GLOBAL ONCOLOGY MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 15 GLOBAL DIABETES MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 16 GLOBAL INFECTIOUS DISEASES MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 17 GLOBAL CARDIOLOGY MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 18 GLOBAL AUTOIMMUNE DISEASES MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 19 GLOBAL DRUG TESTING MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 20 GLOBAL NEPHROLOGY MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 21 GLOBAL OTHERS MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 22 GLOBAL IN-VITRO DIGNOSTICS MARKET BY TEST TYPES SEGMENTATION, 2016 (%)
Chart 23 GLOBAL CORE LABORATORY DIAGNOSITICS MARKET, 2016-2023 (%)
Chart 24 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, 2016-2023 (%)
Chart 25 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USER SEGMENTATION, 2016 (%)
Chart 26 GLOBAL IN-VITRO DIAGNOSTIC MARKET BY GEOGRAPHICAL SEGMENTATION, 2016 (%)
Chart 27 GLOBAL IN-VITRO DIAGNOSTIC MARKET BY GEOGRAPHICAL SEGMENTATION, 2023(%)
Chart 28 IN-VITRO DIAGNOSTICS MARKET REVENUE IN THE NORTH AMERICA, 2016–2023 ($BILLION)
Chart 29 IN-VITRO DIAGNOSTICS MARKET REVENUE IN THE EUROPE REGION, 2016–2023 ($BILLION)
Chart 30 IN-VITRO DIAGNOSTICS MARKET REVENUE IN THE APAC REGION, 2016–2023 ($BILLION)
Chart 31 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT
Chart 32 F. HOFFMANN.LA ROCHE.: BUSINESS UNITS
Chart 33 F. HOFFMANN-LA ROCHE GEOGRAPHICAL PRESENCE
Chart 34 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS
Chart 35 ABBOTT LABORATORIES.: OVERVIEW SNAPSHOT
Chart 36 ABBOTT LABORATORIES.: BUSINESS UNITS
Chart 37 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE
Chart 38 ABBOTT LABORATORIES.: SWOT ANALYSIS
Chart 39 SIEMENS HEALTHINEERS INC.: OVERVIEW SNAPSHOT
Chart 40 SIEMENS HEALTHINEERS INC.: GEOGRAPHIC PRESENCE
Chart 41 SIEMENS HEALTHINEERS INC.: SWOT ANALYSIS
Chart 42 DANAHER CORPORATION: OVERVIEW SNAPSHOT
Chart 43 DANAHER CORPORATION: BUSINESS UNITS
Chart 44 DANAHER CORPORATION: GEOGRAPHIC PRESENCE
Chart 45 DANAHER CORPORATION: SWOT ANALYSIS
Chart 46 THERMO FISHER SCIENTIFIC INC.: OVERVIEW SNAPSHOT
Chart 47 THERMO FISHER SCIENTIFIC INC.: BUSINESS UNITS REVENUE
Chart 48 THERMO FISHER SCIENTIFIC INC.: GEOGRAPHICAL PRESENCE
Chart 49 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
Chart 50 SYSMEX CORP: OVERVIEW SNAPSHOT
Chart 51 SYSMEX CORP: BUSINESS UNIT
Chart 52 SYSMEX CORP: GEOGRAPHIC PRESENCE
Chart 53 SYSMEX CORP.: SWOT ANALYSIS
Chart 1 PEST ANALYSIS OF GLOBAL IN-VITRO DIAGNOSTICS MARKET
Chart 2 RESEARCH METHODOLOGY OF GLOBALIN-VITRO DIAGNOSTICS MARKET
Chart 3 GLOBAL IN-VITRO DIAGNOSTICS MARKET REVENUE FORECAST, 2016–2023 ($BILLION)
Chart 4 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY SEGMENTATION
Chart 5 PORTER 5 FORCES ON GLOBAL IN-VITRO DIAGNOSTISC MARKET
Chart 6 MARKET DYNAMICS – DRO ANALYSIS
Chart 7 DRO – IMPACT ANALYSIS OF GLOBAL IN-VITRO DIAGNOSTICS MARKET
Chart 8 KEY STAKEHOLDERS
Chart 9 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TYPE SEGMENTATION, 2016 (%)
Chart 10 GLOBAL IMMUNOASSAY MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 11 GLOBAL CLINICAL CHEMISTRY MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 12 GLOBAL OTHER MOLECULAR DIAGNOSTICS MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 13 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION, 2016 (%)
Chart 14 GLOBAL ONCOLOGY MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 15 GLOBAL DIABETES MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 16 GLOBAL INFECTIOUS DISEASES MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 17 GLOBAL CARDIOLOGY MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 18 GLOBAL AUTOIMMUNE DISEASES MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 19 GLOBAL DRUG TESTING MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 20 GLOBAL NEPHROLOGY MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 21 GLOBAL OTHERS MARKET REVENUE FORECAST, 2017–2023 ($BILLION)
Chart 22 GLOBAL IN-VITRO DIGNOSTICS MARKET BY TEST TYPES SEGMENTATION, 2016 (%)
Chart 23 GLOBAL CORE LABORATORY DIAGNOSITICS MARKET, 2016-2023 (%)
Chart 24 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, 2016-2023 (%)
Chart 25 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USER SEGMENTATION, 2016 (%)
Chart 26 GLOBAL IN-VITRO DIAGNOSTIC MARKET BY GEOGRAPHICAL SEGMENTATION, 2016 (%)
Chart 27 GLOBAL IN-VITRO DIAGNOSTIC MARKET BY GEOGRAPHICAL SEGMENTATION, 2023(%)
Chart 28 IN-VITRO DIAGNOSTICS MARKET REVENUE IN THE NORTH AMERICA, 2016–2023 ($BILLION)
Chart 29 IN-VITRO DIAGNOSTICS MARKET REVENUE IN THE EUROPE REGION, 2016–2023 ($BILLION)
Chart 30 IN-VITRO DIAGNOSTICS MARKET REVENUE IN THE APAC REGION, 2016–2023 ($BILLION)
Chart 31 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT
Chart 32 F. HOFFMANN.LA ROCHE.: BUSINESS UNITS
Chart 33 F. HOFFMANN-LA ROCHE GEOGRAPHICAL PRESENCE
Chart 34 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS
Chart 35 ABBOTT LABORATORIES.: OVERVIEW SNAPSHOT
Chart 36 ABBOTT LABORATORIES.: BUSINESS UNITS
Chart 37 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE
Chart 38 ABBOTT LABORATORIES.: SWOT ANALYSIS
Chart 39 SIEMENS HEALTHINEERS INC.: OVERVIEW SNAPSHOT
Chart 40 SIEMENS HEALTHINEERS INC.: GEOGRAPHIC PRESENCE
Chart 41 SIEMENS HEALTHINEERS INC.: SWOT ANALYSIS
Chart 42 DANAHER CORPORATION: OVERVIEW SNAPSHOT
Chart 43 DANAHER CORPORATION: BUSINESS UNITS
Chart 44 DANAHER CORPORATION: GEOGRAPHIC PRESENCE
Chart 45 DANAHER CORPORATION: SWOT ANALYSIS
Chart 46 THERMO FISHER SCIENTIFIC INC.: OVERVIEW SNAPSHOT
Chart 47 THERMO FISHER SCIENTIFIC INC.: BUSINESS UNITS REVENUE
Chart 48 THERMO FISHER SCIENTIFIC INC.: GEOGRAPHICAL PRESENCE
Chart 49 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
Chart 50 SYSMEX CORP: OVERVIEW SNAPSHOT
Chart 51 SYSMEX CORP: BUSINESS UNIT
Chart 52 SYSMEX CORP: GEOGRAPHIC PRESENCE
Chart 53 SYSMEX CORP.: SWOT ANALYSIS
